PDE3B

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B · Q13370 · PDE3B on Sugi Atlas →

111,075 patent compounds predicted against PDE3B, 59,748 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Anagrelide (SCHEMBL9411)	1.00	20/20
Cilostamide (SCHEMBL49742)	1.00	20/20
Bemoradan (SCHEMBL121664)	1.00	20/20
SCHEMBL155132	0.70	20/20
Medorinone (SCHEMBL121782)	1.00	19/20
Lixazinone (SCHEMBL143532)	0.77	19/20
Lixazinone (SCHEMBL122949)	0.72	19/20
Revizinone (SCHEMBL27163)	0.50	19/20
Indolidan (SCHEMBL124043)	1.00	17/20
Hydrochloric Acid (SCHEMBL159328)	1.00	17/20
Simendan (SCHEMBL80460)	1.00	16/20
Levosimendan (SCHEMBL83243)	1.00	16/20
Siguazodan (SCHEMBL149133)	0.58	16/20
Imazodan (SCHEMBL148436)	1.00	15/20
Imazodan (SCHEMBL124243)	0.97	15/20
SCHEMBL185627	1.00	14/20
Prinoxodan (SCHEMBL122042)	0.55	14/20
Milrinone (SCHEMBL36947)	1.00	11/20
Quazinone (SCHEMBL120976)	1.00	11/20
SCHEMBL216327	0.53	11/20

Clinical trials — most relevant to PDE3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes	PHASE4	COMPLETED
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis	PHASE4	COMPLETED
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?	PHASE4	COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	PHASE3	NOT_YET_RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer	PHASE3	RECRUITING
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate	PHASE2/PHASE3	RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial	PHASE2	COMPLETED
Effect of Tadalafil on Cerebral Large Arteries in Stroke	PHASE2	COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)	PHASE2	RECRUITING
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study	PHASE2	UNKNOWN
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response	EARLY_PHASE1	UNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
Endurance Performance at Altitude	nan	COMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients	nan	WITHDRAWN
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDE3B binder may also engage these)

Protein	Name	Similarity
Q63085	—	1.000	Q63085 →
Q61409	—	1.000	Q61409 →
Q62865	—	0.993	Q62865 →
PDE3A	cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A	0.992	landscape →
Q9Z0X4	—	0.990	Q9Z0X4 →
Q28C33	—	0.984	Q28C33 →
Q4V7W5	—	0.982	Q4V7W5 →
KAT2B	Histone acetyltransferase KAT2B	0.981	landscape →
Q8K245	—	0.981	Q8K245 →
Q9BY84	—	0.981	Q9BY84 →
O54828	—	0.980	O54828 →
Q3UWM4	—	0.980	Q3UWM4 →
P78524	—	0.980	P78524 →
Q6NRE7	—	0.980	Q6NRE7 →
Q5RHD1	—	0.980	Q5RHD1 →
Q9Y2I9	—	0.980	Q9Y2I9 →
Q6GQL0	—	0.980	Q6GQL0 →
P49140	—	0.979	P49140 →
Q8BMA3	—	0.979	Q8BMA3 →
Q80TJ7	—	0.979	Q80TJ7 →
Q70CQ4	—	0.979	Q70CQ4 →
Q8K4S7	—	0.979	Q8K4S7 →
Q9Z136	—	0.979	Q9Z136 →
Q7TP65	—	0.979	Q7TP65 →
Q80U16	—	0.979	Q80U16 →
Q62925	—	0.979	Q62925 →
P59672	—	0.979	P59672 →
Q9BRS8	—	0.979	Q9BRS8 →
Q02225	—	0.979	Q02225 →
Q3TTA7	—	0.978	Q3TTA7 →